ArticleMolecular diversity2026
Structure-based screening of small-molecule interleukin-23 inhibitors inspired by monoclonal antibody interactions.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Interleukin-23 (IL-23) is a key driver of chronic inflammatory diseases, yet current therapies rely on costly monoclonal antibodies. This study aims to identify small-molecule IL-23 inhibitors using an in silico approach that mimics antibody interactions. The structure of IL-23 and the monoclonal antibody Risankizumab was reconstructed using homology modeling and deep learning. Key binding sites were characterized and used to generate 3D pharmacophore models, which guided virtual screening of compounds from DrugBank and ZINC12 databases. Top candidates were evaluated via ADMET filtering, molecular docking, molecular dynamics simulations and MM/GBSA binding free energy calculations. ZINC20572287 (r3-7) demonstrated stable binding within the IL-23p19 pocket and maintained strong hydrogen bonding over a 600 ns simulation. In contrast, no potent IL-12p40 inhibitors were identified. These findings suggest r3-7 as a promising scaffold for developing cost-effective IL-23-targeted therapeutics.
Indexed as
Identifiers
40549294What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.